Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance.
May LevinMichal StarkYishai OfranYehuda Gérard AssarafPublished in: Cancer cell international (2021)
Our findings emphasize the need for standardized evaluation of key drug transport and metabolism genes as an integral component of routine AML management, thereby allowing for the selection of treatments of choice for individual patients. This approach could facilitate the design of efficacious personalized treatment regimens, thereby reducing relapse rates of therapy refractory disease.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- emergency department
- gene expression
- patient reported outcomes
- diffuse large b cell lymphoma
- clinical practice
- decision making
- bone marrow
- allogeneic hematopoietic stem cell transplantation